Development of Classification Models for Identifying “True” P-glycoprotein (P-gp) Inhibitors Through Inhibition, ATPase Activation and Monolayer Efflux Assays by Rapposelli, Simona et al.
Int. J. Mol. Sci. 2012, 13, 6924-6943; doi:10.3390/ijms13066924 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Development of Classification Models for Identifying “True”  
P-glycoprotein (P-gp) Inhibitors Through Inhibition, ATPase 
Activation and Monolayer Efflux Assays 
Simona Rapposelli 1, Alessio Coi 2, Marcello Imbriani 3 and Anna Maria Bianucci 1,4,* 
1 Department of Pharmaceutical Sciences, University of Pisa, Via Bonanno 6, Pisa 56126, Italy;  
E-Mail: simona.rapposelli@farm.unipi.it 
2 Consorzio Interuniversitario Nazionale per la Scienza e la Tecnologia dei Materiali (INSTM),  
Via Giusti 9, Firenze 50121, Italy; E-Mail: alec@farm.unipi.it 
3 Fondazione S. Maugeri, Via S. Maugeri 4, Pavia 27100, Italy; E-Mail: mimbriani@fsm.it  
4 International Centre for Studies and Research in Biomedicine (ICB) A.s.b.l.,  
Luxembourg L-4947, Luxembourg 
* Author to whom correspondence should be addressed; E-Mail: bianucci@dcci.unipi.it;  
Tel.: +39-050-2219575.  
Received: 22 March 2012; in revised form: 21 May 2012 / Accepted: 31 May 2012 /  
Published: 7 June 2012 
 
Abstract: P-glycoprotein (P-gp) is an efflux pump involved in the protection of tissues of 
several organs by influencing xenobiotic disposition. P-gp plays a key role in multidrug 
resistance and in the progression of many neurodegenerative diseases. The development of 
new and more effective therapeutics targeting P-gp thus represents an intriguing challenge 
in drug discovery. P-gp inhibition may be considered as a valid approach to improve drug 
bioavailability as well as to overcome drug resistance to many kinds of tumours 
characterized by the over-expression of this protein. This study aims to develop 
classification models from a unique dataset of 59 compounds for which there were 
homogeneous experimental data on P-gp inhibition, ATPase activation and monolayer 
efflux. For each experiment, the dataset was split into a training and a test set comprising 
39 and 20 molecules, respectively. Rational splitting was accomplished using a  
sphere-exclusion type algorithm. After a two-step (internal/external) validation, the  
best-performing classification models were used in a consensus predicting task for the 
identification of compounds named as “true” P-gp inhibitors, i.e., molecules able to inhibit 
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P-gp without being effluxed by P-gp itself and simultaneously unable to activate the 
ATPase function. 
Keywords: P-glicoprotein; decision trees; classification model; consensus model; P-gp 
inhibitors; MDR1 ligands 
 
1. Introduction 
P-glycoprotein (P-gp), also known as MDR1, is an ATP-dependent drug efflux pump of 170 kD. It 
is a member of the ABC superfamily and is abundantly expressed in multidrug resistance (MDR) cells 
and produced by the ABCB1 gene [1]. This efflux pump is involved in the protection of tissues of 
several critical organs. It is highly and normally expressed in the liver, intestine, kidney, brain and 
placenta, thus influencing xenobiotic disposition. Consequently, P-gp appears to be an important target 
for the development of new and more effective therapeutics. P-gp plays an important role in multidrug 
resistance to several cytostatic agents [2–5]; in addition, it seems to be involved not only in limiting 
the penetration of many exogenous agents across the blood brain barrier (BBB), but also in the 
aetiology of some neurological disorders [6–10].  
As P-gp is a significant component of the BBB, it limits or prevents the input of several 
chemotherapeutical agents, small peptides, antibiotics, HIV protease inhibitors and antidepressant 
drugs in the central nervous system (CNS). Its high and homogeneous distribution in the CNS suggests 
that this kind of efflux pump may be essential both for brain detoxification and for protection  
against xenobiotics. 
The unexpected reduced permeability through the BBB of several highly lipophilic xenobiotics 
and/or anticancer drugs such as vincristine and doxorubicin may be attributable to the expression of  
P-gp. P-gp pumps several drugs out of the brain capillary endothelial cells, such as doxorubicin, 
vincristine and cyclosporin A, thus limiting the accumulation of these molecules within the endothelial 
cells. On the one hand, this results in the protection of the brain from toxic substances. However, it 
may represent the main limiting factor in the reduced effectiveness of some therapies in the treatment 
of neurodegenerative diseases (i.e., Parkinson’s and Alzheimer’s). Several drugs generally used for the 
treatment of these disorders include P-gp substrates, and consequently their permeability through the 
BBB could be dramatically reduced.  
P-gp inhibition can thus be considered as a valid approach to improve drug bioavailability in tissues 
where P-gp is highly expressed. One potential strategy to counteract multidrug resistance is the  
co-administration of a chemotherapeutic agent with a P-gp inhibitor. Thus, the modulation of P-gp is 
an important goal in overcoming drug resistance in many kinds of tumours characterized by an  
over-expression of this protein. On the other hand, the co-administration of some drugs with known  
P-gp inhibitors could lead to adverse neurotoxic reactions caused by the increased accumulation of 
drugs in the CNS. This is the case for the first and second generations of P-gp modulators (i.e., 
verapamil, biricodar), which resulted in unacceptable toxicity necessitating a reduction in 
chemotherapy doses in clinical trials [11]. 
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Several assays have been used for the identification of P-gp substrates, inhibitors, or both. 
Inhibition experiments (i.e., calcein-AM (acetomethoxy) assays and [3H]-vinblastine transport 
inhibition assay) and the ATP-ase activation assay are commonly used to identify compounds that 
inhibit the transport of known substrates and to gain info regarding pump activation. In addition, the 
monolayer efflux assay, which enables the ratio of basolateral-to-apical (B→A) permeability versus 
apical-to-basolateral (A→B) permeability to be calculated, can be useful for identifying  
P-gp substrates [12]. 
Our study was carried out using a unique dataset of 59 compounds for which there were data 
referring to inhibition, ATPase activation and monolayer efflux assays. The aim was to develop 
classification models (CMs) to identify “true” P-gp inhibitors. We define them as being “true” in the 
sense that they are compounds that are able to inhibit P-gp, without being effluxed by P-gp itself and 
simultaneously unable to activate the ATPase function. We originally introduced this definition [13] 
based on criteria suggested by Polli et al. [12]. Applying this hypothesis, the simultaneous use of the 
three types of classification models could help to identify new chemical entities according to the 
definitions summarized in Table 1.  
Table 1. Summary of definitions for “true” p-glycoprotein (P-gp) inhibitors, P-gp 
substrates or non-substrates. 
Definition P-gp Inhibition ATPase activation Efflux 
“True” inhibitor Y N N 
Substrate Y Y Y 
Non-substrate N N N 
Inhibition assay, Y: inhibitor; ATPase activation, Y: activator; efflux, Y: effluxed compound. 
A “true” P-gp inhibitor is positive only in the inhibition assay (it is not effluxed, nor does it activate 
the pump); a substrate is positive in all three assays (it activates the pump, it is effluxed, and inhibits 
the transport of a reference substrate, probably with a competitive mechanism); a non-substrate is 
negative in all three assays. 
Regarding the specific assays used to label the compounds, the calcein AM assay was used to assess 
whether or not a compound acts as a P-gp inhibitor. The calcein fluorescence is measured in a relative 
fluorescence unit (RFU). The percentage maximum response is defined by dividing the test 
compound’s RFU response by the elacridar (a potent, specific Pgp inhibitor) RFU response. 
The drug-stimulated ATPase activity (nmol/min/mg of protein) is determined as the difference 
between the amounts of inorganic phosphate released from ATP in the absence and presence of 
vanadate. Drug-stimulated Pgp ATPase activity is reported as fold-stimulation in relation to the basal 
Pgp ATPase activity in the absence of drug. 
Regarding the monolayer efflux assay, the ratio of the B→A/A→B apparent permeability (Papp) 
values is calculated. The involvement of a Pgp-mediated efflux mechanism (class Y) is suggested 
when the B→A/A→B ratio is ≥2.1. 
The predictive power of the developed CMs was estimated using a test set selected for each 
experiment from the initial dataset of 59 compounds. The best-performing models evaluated in terms 
of robustness and predictivity, obtained within each experiment, were used as a consensus model for a 
Int. J. Mol. Sci. 2012, 13 6927 
 
 
further predictive task performed on an additional external set of compounds already synthesized by  
us [13–16]. All models were validated through currently accepted criteria for statistical analysis [17]. 
2. Results and Discussion 
2.1. Leave-One-Out cross Validation and Test Set Prediction  
Several classification models were built by using random tree (RT) and C4.5 algorithms and, for 
each model, specific parameters were changed, as previously described.  
Leave-One-Out Cross-Validation (LOO-CV) was used to estimate the classification results on the 
training sets of each experiment: on the basis of the computed statistical parameters mentioned in 
Section 3.3, only CMs with an accuracy ≥ 70%, Matthews Correlation Coefficient (MCC) ≥ 0.40,  
K ≥ 0.40 and Area Under the ROC Curve (AUC) ≥ 0.60 were selected. Tables 2–4 report the statistical 
parameters such as sensitivity (True Positives, TP), specificity (True Negatives, TN), accuracy, MCC, 
K statistic, and AUC obtained from LOO-CV and from the prediction on the test sets for the best 
decision trees developed in the three experiments. At least one model developed with the C4.5 
algorithm was reported for each experiment, even when statistics did not satisfy the requested criteria. 
Table 2. Classification models on P-gp inhibition experiment: leave-one-out (LOO)  
cross-validation statistical parameters and prediction task on the test set.  
Model LOO-cross validation statistics Test set statistics 
TP TN Acc MCC K AUC TP TN Acc 
RT(S9 K10) 62.5 87.0 76.9 0.51 0.51 0.75 90.0 50.0 70.0 
RT(S10 K11) 68.8 82.6 76.9 0.52 0.52 0.76 60.0 80.0 70.0 
RT(S1 K11) 68.8 78.3 74.4 0.47 0.47 0.74 90.0 70.0 80.0 
C4.5 37.5 65.2 53.8 0.19 0.48 0.52 60.0 50.0 55.0 
TP: True positives (sensitivity for inhibitor, class Y); TN: true negatives (specificity for class N);  
Acc: Accuracy; MCC: Matthews correlation coefficient; K: K statistic; AUC: Area Under the ROC Curve;  
S: seed number; K: number of randomly chosen molecular descriptors at each node. 
Table 3. Classification models on ATPase activation experiment: LOO cross-validation 
statistical parameters and prediction task on the test set.  
Model 
LOO-cross validation statistics Test set statistics 
TP TN Acc MCC K AUC TP TN Acc 
RT(S5 K3) 84.2 80 82.1 0.64 0.64 0.82 80.0 60.0 70.0 
RT(S10 K2) 73.7 80 76.9 0.54 0.54 0.77 60.0 80.0 70.0 
RT(S10000 K8) 73.7 70 71.8 0.44 0.44 0.72 70.0 80.0 75.0 
C4.5 89.5 75 82.1 0.65 0.64 0.86 60.0 50.0 55.0 
TP: True positives (sensitivity for ATPase activator, class Y); TN: true negatives (specificity for class N); 
Acc: Accuracy; MCC: Matthews correlation coefficient; K: K statistic; AUC: Area Under the ROC Curve;  
S: seed number; K: number of randomly chosen molecular descriptors at each node. 
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Table 4. Classification models on monolayer efflux experiment: LOO cross-validation 
statistical parameters and prediction task on the test set.  
Model LOO-cross validation statistics Test set statistics 
TP TN Acc MCC K AUC TP TN Acc 
RT(S80 K15) 79.2 60 71.8 0.40 0.40 0.70 80.0 70.0 75.0 
RT(S20 K4) 83.3 66.7 76.9 0.51 0.51 0.75 80.0 60.0 70.0 
RT(S80 K14) 83.3 60 74.4 0.45 0.44 0.72 70.0 60.0 65.0 
RT(S30 K4) 70.3 73.3 71.8 0.44 0.43 0.72 80.0 50.0 65.0 
RT(S1000 K14) 79.2 66.7 74.4 0.46 0.46 0.73 60.0 70.0 65.0 
C4.5 75.0 40.0 61.5 0.16 0.16 0.41 100.0 40.0 70.0 
TP: True positives (sensitivity for effluxed compounds, class Y); TN: true negatives (specificity for class N); 
Acc: Accuracy; MCC: Matthews correlation coefficient; K: K statistic; AUC: Area Under the ROC Curve;  
S: seed number; K: number of randomly chosen molecular descriptors at each node. 
Looking at the statistical parameters (in particular, accuracy, MCC and K statistic) obtained from 
LOO-CV, the models are expected to possess a good predictive power; however, a second validation 
step was carried out on a test set selected for each experiment (see Section 3.1) in order to support this 
result. All compounds of the test set belong to the applicability domains (AD) defined by the training 
set of each experiment (see Section 3.4 for a definition of AD).  
With regard to the inhibition experiment, 19 molecular descriptors were used for developing the 
models. After the two-step validation, three best-performing decision trees (RT method) were selected—
see Figure S1 in Supporting Information for their graphical representation.  
The RT(S10 K11) model produced the best predictions for the classification of the P-gp inhibition 
(Table 2), showing the highest level of similarity between the internal LOO-CV, with a TP of 68.8 and 
TN of 82.6%, and the external test set, with a TP of 60 and TN of 80%. RT(S10 K11) also showed the 
highest MCC, K and AUC compared to the other classification models for P-gp inhibition. On the other 
hand, C4.5 showed the lowest values for each parameter in the internal LOO-CV and external validation 
on the test set, in comparison with the other models referring to the P-gp inhibition experiment. 
RT(S9 K10) was found by randomly choosing a maximum of 10 molecular descriptors (K10) at 
each node; six molecular descriptors were involved in the model (Table 5). RT(S10 K11) and RT(S1 
K11) were found by randomly choosing a maximum of 11 molecular descriptors at each node; both 
models were finally based on five molecular descriptors. 
Table 5. Number and type of molecular descriptors involved in each model developed for 
the inhibition, ATPase activation, and monolayer efflux experiments. 
Inhibition 
Model n° of Molecular Descriptors involved 
RT(S9 K10) 6 
RT(S10 K11) 5 
RT(S1 K11) 5 
Molecular descriptor n° of models in which the descriptor is involved 
XLogP 3  
AMR 3 
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Table 5. Cont. 
Inhibition 
nBondsS3 3 
Ghose-Crippen LogKow 3 
TopoPSA 2 
PubchemFP544 1 
C1SP2 1 
ATPase activation 
Model n° of Molecular Descriptors involved 
RT(S5 K3) 10 
RT(S10 K2) 9 
RT(S10000 K8) 7 
Molecular descriptor n° of models in which the descriptor is involved 
TopoPSA 3 
MLFER_E 3 
n6Ring 3 
nHBDon 3 
nHBAcc 3 
nT6Ring 3 
nRing 2 
PubchemFP256 2 
PubchemFP392 1 
Pubchem FP437 1 
PubchemFP495 1 
PubchemFP592 1 
PubchemFP607 1 
Monolayer efflux 
Model n° of Molecular Descriptors involved 
RT(S30 K4) 10 
RT(S20 K4) 9 
RT(S80 K14) 8 
RT(S80 K15) 7 
RT(S1000 K14) 6 
Molecular descriptor n° of models in which the descriptor is involved 
nBondsS3 5 
MLFER_E 5 
XLogP 4 
C3SP2 4 
MLFER_A 4 
Ghose-Crippen LogKow 4 
AMR 3 
C2SP2 2 
nHBAcc 2 
nRing 2 
Mannhold LogP 1 
C2SP3 1 
PubchemFP299 1 
PubchemFP737 1 
SubFPC275 1 
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Only seven of the initially exploited 19 molecular descriptors were involved in these decision trees: 
XLogP, molar refractivity (AMR), number of single bonds, excluding bonds with hydrogen atoms and 
aromatic bonds (nBondsS3), and Ghose-Crippen LogKow (ALogP) was common to all models  
(Table 5). Topological Polar Surface Area (TopoPSA) was common to models RT(S9 K10) and 
RT(S10 K11). The SMARTS pattern: O:C-C:O (PubchemFP544) and a doubly bound carbon, bound 
to another carbon, = C–C– (C1SP2) were only involved in RT(S1 K11) and RT(S9 K10), respectively. 
XLogP created the highest separation (13/4) of the Y/N compounds; most of the inhibitors had a 
XLogP ≥ 1.6 (13/16 Y compounds, as observed in RT(S9 K10)); a topological polar surface area  
> 23.76 Å2, and a Ghose-Crippen LogKow (ALogP) ≥ −0.76 (12/16 class Y compounds, as observed in 
RT(S9 K10)). Having a high PSA corresponds to a high proportion of electronegative elements  
(i.e., nitrogen and oxygen atoms) and accounts for the poor penetration of molecules in a hydrophobic 
environment (i.e., biological membranes). However, it may account for their easy penetration in 
hydrophilic environments, such as the core of transporter proteins. Generally, molecules with a  
PSA > 140 Å2 are believed to have a low capacity for penetrating cell membranes, while those with 
PSA < 60 Å2 are easily absorbed [18]. Our finding is in agreement with Gadhe et al. [19] who carried 
out a CoMFA and HQSAR study, highlighting the importance of the presence of electronegative 
elements for a compound to be an inhibitor. Of the inhibitors belonging to our training set and 
characterized by a high proportion of electronegative atoms, nitrendipine, nicardipine and nifedipine 
are examples of compounds bearing a nitro group. This aspect also was also observed by Gadhe et al. 
who found that a nitro group (together with methoxy and ether) can lead to a good inhibitory potency. 
For the ATPase activation experiment, 18 molecular descriptors were used for developing the 
models. After LOO-CV and the prediction task on the test set, three best-performing decision tree 
models (RT method) were selected—see Figure S2 in Supporting Information for their schematic 
representation.  
The RT(S5 K3) and RT(S10 K2) models produced the best predictions for the classification of the 
ATPase activation experiment (Table 3). The RT(S5 K3) and RT(S10 K2) models showed the best 
similarity between the internal LOO-CV, with a TP of 84.2 and 73.7% and a TN of 80%, and the 
external test set, with a TP of 80 and 60% and TN of 60 and 80%, respectively. RT(S5 K3) showed the 
highest MCC, K and AUC, compared to the other classification models for the ATPase activation 
experiment. Unlike the models developed with the RT algorithm, C4.5 showed the lowest values for 
each parameter in the external test set.  
RT(S10 K2), RT(S5 K3) and RT(S10000 K8) were found by randomly choosing a maximum of 2, 
3 and 8 molecular descriptors at each node; the models were based on 9, 10, and 7 descriptors, 
respectively (Table 5). 
Finally, of the 18 descriptors exploited in developing the models, only 13 were involved in these 
decision trees and six are common to all the selected decision trees (Table 5): topological polar surface 
area (TopoPSA), excessive molar refraction (MLFER_E), number of six-membered rings (n6Ring), 
number of H-bond donors (nHBDon), number of H-bond acceptors (nHBAcc), and number of six 
membered rings, including the fused ones (nT6Ring). Two molecular descriptors, number of rings 
(nRing) and heteroaromatic rings (PubchemFP256), were common to RT(S5 K3) and RT(S10 K2). 
The detailed atom neighbourhood pattern C(–C)(–N)(=C) (PubchemFP437) and the simple SMARTS 
pattern N–C–C–C–C (PubchemFP592) were involved in RT(S5 K3). The simple SMARTS patterns  
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C–N–C:C and N–C–C–C:C) (Pubchem FP495 and PubchemFP607) were involved in RT(S10 K2). 
Finally, the simple atom nearest neighbour pattern N(~C) (~C) (~H) (PubchemFP392) was only 
present in RT(S10000 K8).  
Looking at RT(S10 K2) (Figure S2 in Supporting Information), we observe that all the considered 
ATPase activators have a polar surface area higher than 29.77 Å2. This is in agreement with Fernandes 
and Gattass, who analyzed the chemical properties of some known P-gp substrates and their results 
supported the hypothesis that P-gp pumps out substrates with a high TopoPSA [20]. 
Looking at the decision trees for the ATPase activation experiment (Figure 2 in Supporting 
Information), highlights that although the trees do not indicate a clear separation between activators 
and non-activators: in general, most of the ATPase activators have a number of H-bond donors 
(nHBDon) < 3 and a number of H-bond acceptors (nHBAcc) < 9, an excessive molar refraction 
(MLFER_E) ranging between 1.92 and 3.64 and they have at least one the N–C–C–C:C pattern  
(where “:” refers to an aromatic bond) (PubchemFP607). Furthermore, most of the non-activators have 
more than two six-membered rings (n6Ring).  
For the monolayer efflux experiment, 22 molecular descriptors were used to develop the models. 
After the two-step statistical validation, five best-performing decision tree models (RT method) were 
selected—see Figure S3 in Supporting Information for their graphical representation. 
The RT(S20 K4) model produced the best predictions for the classification of the monolayer efflux 
experiment (Table 4). This model also showed the highest level of similarity between the internal 
LOO-CV, with a TP of 83.3 and a TN of 66.7%, and the external test set, with a TP of 80 and TN of 
60%. Moreover, RT(S20 K4) showed the highest MCC, K and AUC, compared to the other 
classification models for the monolayer efflux experiment. On the other hand, C4.5 showed the lowest 
values for each parameter in the internal LOO-CV and external test set, compared to each model in the 
monolayer efflux experiment. 
RT(S20 K4) and RT(S30 K4) were constructed by randomly choosing a maximum of four 
molecular descriptors at each node. RT(S80 K14) and RT(S1000 K14) were obtained by choosing the 
optimal descriptors from the 14 descriptors available, and RT(S80 K15) was constructed by randomly 
choosing a maximum of 15 molecular descriptors at each node. The final models were based on 9, 10, 
8, 6, and 7 descriptors, respectively (Table 5). 
Lastly, only 14 of the exploited 22 molecular descriptors were involved in these decision trees: the 
number of single bonds, excluding bonds with hydrogen atoms and aromatic bonds (nBondsS3) and 
excessive molar refraction (MLFER_E), were common to all five decision trees (Table 5). XLogP, a 
double bond C atom bound to three other C atoms (C3SP2), the overall summation solute H-bond 
acidity (MLFER_A), and Ghose-Crippen LogKow (ALogP), were common to four out of five models. 
Molar refractivity (AMR) was involved in RT(S80 K15), RT(S20 K4), and RT(S80 K14); double 
bond C atom bound to two other C atoms (C2SP2), number of H-bond acceptors (nHBAcc), and 
number of rings (nRing) were common to two out of five decision trees. Finally, Mannhold LogP 
(MLogP) and simple atom pair N-H (PubchemFP299), count of heterocycles (SubFPC275), single 
bound C atom bound to two other C atoms (C2SP3) and complex SMARTS pattern Cc1cc(N)ccc1 
(PubchemFP737) were only involved in RT(S20 K4), RT(S80 K15), and RT(S30 K4), respectively. 
The graphical representation of the decision trees (Figure S3 in Supporting Information) highlights 
that 21 out of 24 of the effluxed compounds have at least 12 single bonds (excluding bonds with 
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hydrogens and aromatic bonds) (nBondsS3), nBondsS3 molecular descriptor also marks the highest 
separation (22/6) among effluxed(Y)/non-effluxed(N) compounds. A total of 23 out of 24 effluxed 
compounds have a MLFER_E ≥ 1.52, and less than six double bound C atoms bound to three other C 
atoms (C3SP2). At least 20 of the 24 effluxed compounds have a Mannhold LogP (MLogP) ≥ 2.51, 
and almost 17/24 have almost 3 single bound C atom bound to two other C atoms (C2SP3), almost a 
simple atom pair N-H (PubchemFP299), less than five heterocycles (SubFPC275) and less than five 
rings (nRing). 
In summary, the molecular descriptors characterizing the best-performing classification models 
appear to be involved (within each experiment) in different trees showing comparable performances. 
This can be considered as a proof of the stability and reliability of the models, and suggests that the 
performance depends on the sets of molecular descriptors chosen for each experiment (the selection of 
descriptors is described in Section 3.1). 
Furthermore, detailed analysis of the decision trees in the three experiments suggested a pool of 
molecular features that can help in the development of new chemical entities potentially endowed with 
a profile typical of a “true” inhibitor. Some of them, (e.g., polar surface area and LogP for the 
inhibition experiment and nBondsS3 for the efflux experiment), gave quite a clear separation between 
Y/N compounds. 
2.2. Consensus Modelling and Prediction Task on an Additional External Set  
Since all the models were reasonably accurate with regard to the prediction on the test set 
compounds, a consensus model was built for each experiment, by considering the predictions and 
taking into account the applicability domain of each individual model. The statistical parameters for 
LOO-cross validation and for the predictive task on the test sets were calculated using a majority 
voting criteria (i.e., when the majority of models constituting the consensus model classify a 
compound as Y (or N), the prediction output of the consensus model is Y (or N)); results are reported 
in Table 6. 
Table 6. Consensus models for inhibition, ATP-ase activation and monolayer  
efflux experiments.  
 LOO-cross validation statistics Test set statistics 
Model TP (Y) TN (N) Acc MCC K AUC TP (Y) TN (N) Acc 
Inhibition 68.8 95.7 84.6 0.67 0.67 0.82 90.0 70.0 80.0 
ATPase activation 78.9 75 76.9 0.54 0.54 0.84 70.0 80.0 75.0 
Monolayer efflux 83.3 66.7 76.9 0.44 0.51 0.75 80.0 70.0 75.0 
TP: True positives; TN: true negatives; Acc: Accuracy; MCC: Matthews correlation coefficient; K: K 
statistic; AUC: Area Under the ROC Curve; S: seed number; K: number of randomly chosen molecular 
descriptors at each node. 
The results showed that the prediction accuracies of the consensus models, considering the 
statistical parameters obtained for both the LOO-CV and for the prediction task on test sets, were 
generally better than those of any individual model. This is highlighted in the inhibition experiment 
where the best models (RT(S9 K10) and RT(S10 K11)) showed an accuracy of 76.9% and a  
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MCC = 0.51–0.52 on LOO-CV and an accuracy on the test set of 70%. The consensus model shows an 
improved accuracy for both LOO-CV and the test set prediction (84.6 and 80%, respectively) and a 
MCC = 0.67. 
The consensus models were tested on the external set constituted by compounds that we had 
previously synthesized and tested in order to further evaluate the power of the consensus prediction. 
All the external set compounds belong to the applicability domain defined by each training set 
constituting the consensus models. Results of the prediction task are reported in Table 7.  
Table 7. Consensus models statistics for the prediction task on the additional external set.  
 External set statistics 
Model TP (Y) TN (N) Accuracy 
Inhibition 77.1 83.3 77.8 
ATPase activation 75.0 71.4 72.3 
Monolayer efflux 74.4 100.0 76.6 
TP: True positives; TN: true negatives; Acc: Accuracy; Y: inhibitor, ATPase activator, or  
effluxed compound. 
The overall accuracy is similar to that observed on the test sets and comparable to that found by 
other studies on P-gp substrates [21,22]. 
As observed in Section 2.1, only two compounds of this additional external set, II_14a and II_15a, 
are considered effective “true” inhibitors; since they inhibit P-gp with a higher power than elacridar, 
they do not activate ATPase, nor are they effluxed by P-gp. The consensus models correctly predict 
these two compounds and the descriptor nBondsS3 appear to be determinant in identifying them, in 
particular among the compounds of series “III”: II_14a and II_15a have less than 12 single bonds 
(excluding bonds with H atoms and aromatic bonds). In addition, II_11b, II_13a, II_13b, II_16a, 
II_17a, II_17b and II-23 have nBondsS3 < 12, however, they are discarded by the consensus models as 
“true” inhibitors probably because of their polar surface area which is not in the ideal range (23.76–
29.77 Å2) for a compound that can inhibit P-gp without activating ATP-ase. 
3. Experimental Section  
3.1. Dataset and Molecular Descriptors 
The classification models were developed and validated using biological data referring to 59 
compounds taken from Polli et al. [12] belonging to heterogeneous chemical classes and for which 
homogeneous biological data referring to inhibition, ATPase activation and monolayer efflux assays 
were available (Table 8). 
Table 8. Dataset of 59 compounds, with their IAE profile. 
Compound Inhibitor ATPase 
activator 
Efflux Compound Inhibitor ATPase 
activator 
Efflux 
Amantadine N N N Testosterone Y N N 
Chlorpheniramine N N N Chlorpromazine Y Y N 
Doxorubicin N N N Ketoconazole Y Y N 
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Table 8. Cont. 
Compound Inhibitor ATPase 
activator 
Efflux Compound Inhibitor ATPase 
activator 
Efflux 
Itraconazole N N N Mebendazole Y Y N 
Lidocaine N N N Midazolam Y Y N 
Mannitol N N N Nicardipine Y Y N 
Methotrexate N N N Nifedipine Y Y N 
Practolol N N N Nitrendipine Y Y N 
Propranolol N N N Verapamil Y Y N 
Pyridostigmine N N N Chloroquine N N Y 
Ranitidine N N N Cimetidine N N Y 
Sumatriptan N N N Colchicine N N Y 
Triamterene N N N Daunorubicin N N Y 
Yohimbine N N N Dexamethasone N N Y 
Amprenavir Y Y Y Etoposide N N Y 
Diltiazem Y Y Y Hoechst 33342 N N Y 
Dipyridamole Y Y Y Mitoxantrone N N Y 
Loperamide Y Y Y Neostigmine N N Y 
Loratadine Y Y Y Puromycin N N Y 
Monensin Y Y Y Vincristine N N Y 
Nelfinavir Y Y Y Vinorelbine N N Y 
Prazosin Y Y Y Clarythromycin N Y Y 
Quinidine Y Y Y Eletriptan N Y Y 
Reserpine Y Y Y Emetine N Y Y 
Ritonavir Y Y Y Erythromycin N Y Y 
Saquinavir Y Y Y Indinavir N Y Y 
Terfenadine Y Y Y Taxol N Y Y 
Vinblastine Y Y Y Trimethoprim N Y Y 
Elacridar Y N N Cyclosporin A Y N Y 
GW420867 Y N N     
Of the 59 selected compounds, 26 act as inhibitors (class Y) and 33 do not (class N); 29 compounds 
stimulate ATPase activity (class Y) and 30 are not ATPase activators (class N); 34 compounds are 
effluxed (B→A/A→B ratio > 2.1) and 25 do not undergo efflux. Of these, only elacridar, GW420867, 
and testosterone are considered to be “true”-inhibitors (YNN profile), with elacridar being the most 
potent. This binary classification was performed according to thresholds defined for each assay [12].  
For the P-gp inhibition experiment, in the calcein AM assay the percentage maximum response is 
defined by dividing the test compound’s RFU response by the elacridar RFU response. All compounds 
with a response < 10% of the maximum were labelled as negative in the assay (class N). Vinorelbine, 
vincristine, and propranolol had a maximum response between 6% and 12%, thus belonging to the 
non-confident zone, a region where it is difficult to classify a compound as “Y” or “N”. However, 
since these three compounds had a response <10% of maximum, they were labelled as “N” [12].  
Drug-stimulated Pgp ATPase activity was reported as fold-stimulation in relation to the basal Pgp 
ATPase activity in the absence of drugs (DMSO control). A compound was classified as an ATPase 
activator (class Y) if the fold-stimulation was > 2 over the DMSO control. Daunorubicin fell into the 
Int. J. Mol. Sci. 2012, 13 6935 
 
 
non-confident range of ATPase stimulation (between 1.5 and 2.0); however, because the stimulation 
ratio was below 2-fold, the compound was labelled as “N” [12].  
Regarding the monolayer efflux assay, a Pgp-mediated efflux mechanism (class Y) is involved if 
the B→A/A→B ratio is ≥ 2.1. For compounds with B→A/A→B ratios between 1.5 and 2.0, a follow-up 
experiment with 2 μM elacridar was completed to confirm that the compound was effluxed [12].  
In this study, aimed at developing classification models for the identification of “true” P-gp 
inhibitors, a unique dataset was exploited for which homogeneous biological data of inhibition, 
ATPase activation and efflux assays were available. We used an initial dataset containing biological 
data characterized by the required homogeneity but, at the same time, characterized by low variability. 
In fact, the data came from the same research group and were acquired by using the same experimental 
protocol, which ensures that reliable models are obtained. Although the limited size of the dataset may 
lead to the development of models characterized by a limited applicability domain, the creation of a 
consensus model for each type of experiment should help to overcome this problem. The overall 
coverage of chemical space afforded by the consensus model is expected to be high, because it is rare 
to have an unknown compound outside of the defined applicability domain of all available models that 
constitute the consensus model. 
Looking at the number of compounds for each class, it can be noted that the three datasets are quite 
well balanced, which is a critical requirement for the development of a classification model [23].  
The predictive power of the classification models was also tested on an external set made up of 47 
derivatives which we had already synthesized and tested (Table 9) [13–16]. 
Table 9. External set of 47 synthesized compounds. Suffix I, II, and III refer to  
references [13–15] respectively; MV181 is taken from ref [16]. Inhibitors with a potency 
similar to or higher than elacridar are reported in bold in the second column. 
Compound Inhibitor ATPase 
activator 
Efflux Compound Inhibitor ATPase 
activator 
Efflux 
I_8b Y N Y III_7c Y Y Y 
II_11a Y N N III_7d Y Y Y 
II_11b Y N Y III_8a Y Y Y 
II_13a Y N Y III_8b Y Y Y 
II_13b Y N Y III_8c Y Y Y 
II_14a Y N N III_8d Y Y Y 
II_14b Y Y Y III_9a Y N Y 
II_15a Y N N III_9b Y N Y 
II_15b Y N Y III_9c Y N Y 
II_16a Y N Y III_9d Y N Y 
II_16b Y N Y III_10a Y N Y 
II_17b Y Y N III_10b Y N Y 
II_23 Y N Y III_10c Y N Y 
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Table 9. Cont. 
Compound Inhibitor ATPase 
activator 
Efflux Compound Inhibitor ATPase 
activator 
Efflux 
II_25 Y N Y III_10d Y N Y 
II_26 Y N Y III_11a Y N Y 
II_27 Y N Y III_11b Y N Y 
III_5a Y N Y III_11c Y N Y 
III_5b Y N Y III_11d Y N Y 
III_5c Y N Y III_12a Y Y Y 
III_5d Y N Y III_12b Y N Y 
III_6b Y N Y III_12c Y N Y 
III_6c Y N Y III_12d Y Y Y 
III_7a N Y Y MV181 N N Y 
III_7b Y Y Y     
Inhibition assay, Y: inhibitor; ATPase activation, Y: activator; efflux, Y: effluxed compound. 
All 47 selected compounds were tested for inhibition, ATPase activation and monolayer efflux, and 
were labelled as Y/N. In terms of the inhibition assay, since almost all the synthesized compounds 
(except III_7a and MV181) are labelled as inhibitors with a potency higher than verapamil, seven  
non-inhibitors (I_5a–b, I_6a–b, I_7a–b, and I_8a) from reference [14] were added in order to increase 
the N class, and to better assess the classification power of the models on our synthesized compounds. 
A total of 26 out of 45 inhibitors were stronger than elacridar, of which only two (II_14a, II_15a) are 
considered as “true” inhibitors, since they do not activate ATPase and are not effluxed by P-gp. 
Molecular descriptors were calculated by PaDEL, a software that enables the computation of 2D 
and 3D descriptors and several types of fingerprints [24]. A total of 696 molecular descriptors and 
Pubchem fingerprints and substructure fingerprints [25] were calculated for compounds of both the 
modelling and the external set (Table 10). 
Table 10. Molecular descriptors calculated by PaDEL. 
Descriptor Type Descriptor ID Class 
AcidicGroupCount nAcid 2D 
ALOGP ALogP, ALogP2, AMR 2D 
APol apol 2D 
Aromatic atoms count naAromAtom 2D 
Aromatic bonds count nAromBond 2D 
Atom count nAtom, nHeavyAtom, nH, nB, nC, nN, nO, nS, nP, nF, 
nCl, nBr, nI 
2D 
BasicGroupCount nBase 2D 
BondCount nBonds, nBonds2, nBondsS, nBondsS2, nBondsS3, 
nBondsD, nBondsD2, nBondsT, nBondsQ 
2D 
BPol bpol 2D 
Carbon types C1SP1, C2SP1, C1SP2, C2SP2, C3SP2, C1SP3, C2SP3, 
C3SP3, C4SP3 
2D 
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Table 10. Cont. 
Descriptor Type Descriptor ID Class 
HBondAcceptorCount nHBAcc, nHBAcc2, nHBAcc3, nHBAcc_Lipinski 2D 
HBondDonorCount nHBDon, nHBDon_Lipinski 2D 
LargestChain nAtomLC 2D 
LargestPiSystem nAtomP 2D 
LongestAliphaticChain nAtomLAC 2D 
MannholdLogP MLogP 2D 
McGowanVolume McGowan_Volume 2D 
MLFER MLFER_A, MLFER_BH, MLFER_BO, MLFER_S, 
MLFER_E, MLFER_L 
2D 
Ring count nRing, n3Ring, n4Ring, n5Ring, n6Ring, n7Ring, n8Ring, 
n9Ring, n10Ring, n11Ring, n12Ring, nG12Ring,  
nFRing, nF4Ring, nF5Ring, nF6Ring, nF7Ring, nF8Ring, 
nF9Ring, nF10Ring, nF11Ring, nF12Ring, nFG12Ring,  
nTRing, nT4Ring, nT5Ring, nT6Ring, nT7Ring, nT8Ring, 
nT9Ring, nT10Ring, nT11Ring, nT12Ring, nTG12Ring 
2D 
Rotatable bonds count nRotB 2D 
Rule of five LipinskiFailures 2D 
Topological polar surface 
area 
TopoPSA 2D 
van der Waals volume VABC 2D 
Weight MW 2D 
XLogP XLogP 2D 
Charged partial surface area PPSA-1, PPSA-2, PPSA-3,  
PNSA-1, PNSA-2, PNSA-3,  
DPSA-1, DPSA-2, DPSA-3,  
FPSA-1, FPSA-2, FPSA-3,  
FNSA-1, FNSA-2, FNSA-3,  
WPSA-1, WPSA-2, WPSA-3,  
WNSA-1, WNSA-2, WNSA-3,  
RPCG, RNCG, RPCS, RNCS, THSA, TPSA, RHSA, RPSA 
3D 
Moment of inertia MOMI-X, MOMI-Y, MOMI-Z, MOMI-XY, MOMI-XZ, 
MOMI-YZ, MOMI-R 
3D 
Pubchem fingerprint Hierarchal element counts 
Rings in a canonic Extended Smallest Set of Smallest Rings 
(ESSSR) ring set 
Simple atom pairs 
Simple atom nearest neighbours 
Detailed atom neighbourhoods 
Simple SMARTS patterns 
Complex SMARTS patterns 
fingerprint 
Substructure fingerprint - fingerprint 
Substructure fingerprint 
count 
-  
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For each experiment, the dataset was split into a training set of 39 molecules and a test set of 20. 
Test sets were rationally selected using the calculated molecular descriptors. Each molecule of the 
initial dataset was represented as a point in a multi-dimensional space defined by all the descriptors. 
The dataset was thus split into a training/test set pair for each experiment, so that points representing 
both training and test sets were distributed within the whole descriptor space occupied by the entire 
dataset, and each point of the test set was close to at least one point of the training set. This ensures 
that the similarity principle is followed when activity is predicted on the test set. Rational splitting was 
accomplished using a Sphere-Exclusion type algorithm [26], which we had subsequently optimized [27]. 
However, the selection was “driven” so that the two classes of each experiment were equally 
represented in the test set (10 compounds for each class Y/N) as commonly suggested for binary 
classification models [23]. The compounds selected for each test set are shown in Table 11. 
Table 11. Selected test sets for inhibition, ATPase activation and monolayer efflux experiments. 
Inhibition ATPase activation Monolayer efflux 
Vinblastine Dipyridamole Vinblastine 
Terfenadine Vinblastine Taxol 
Ritonavir Taxol Ritonavir 
Loratadine Ritonavir Clarythromycin 
Monensin Clarithromycin Indinavir 
Reserpine Monensin Emetine 
Nelfinavir Amprenavir Dipyridamole 
Dipyridamole Reserpine Monensin 
Ketoconazole Trimethoprim Reserpine 
Loperamide Prazosin Colchicine 
Vincristine Doxorubicin Itraconazole 
Taxol Vincristine Verapamil 
Vinorelbine Mitoxantrone Nicardipine 
Clarithromycin Etoposide Yohimbine 
Itraconazole Methotrexate Chlorpromazine 
Etoposide Puromycin Midazolam 
Daunorubicin Vinorelbine Nifedipine 
Mitoxantrone Triamterene Methotrexate 
Hoechst 33342 Mannitol Testosterone 
Emetine Cimetidine Practolol 
For each experiment, the initial high number of descriptors was pre-selected, which enabled us to 
leave out of the subsequent modelling process any descriptors that do not change significantly across 
the molecules of the dataset or those that were too strictly correlated (i.e., that do not contain the 
desired degree of information). Descriptors with constant values and those showing an inter-correlation 
higher than 0.95 were thus discarded. 
After that, in order to determine the right combination of molecular descriptors to be used in the 
search for good models, the CfsSubsetEval attribute evaluator [28] within the WEKA software [29], 
was applied and a genetic algorithm was chosen as the search method. This method evaluates the 
worth of a subset of attributes by considering the individual predictive ability of each feature along 
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with the degree of redundancy between them. Subsets of features that are highly correlated with the 
class of compound while having low inter-correlation are preferred. Using a Leave-One-Out (LOO) 
cross-validation on each training set, and performing 10 runs with different seed numbers to obtain 
averaged results, subsets of molecular descriptors were selected according to the average percentage of 
a ranking value. Following this method, the molecular descriptors were reduced to three subsets of 19, 
18, and 22 descriptors which were used to develop classification models for the inhibition, ATPase 
activation and monolayer efflux experiments, respectively. 
3.2. Classification Methods  
Decision trees are one of the most widely used forms of machine learning enabling data mining for 
predictive purposes. In this study, Random tree and C4.5 [30] algorithms available in WEKA were 
used to develop predictive CMs. 
The Random Tree algorithm builds a tree that considers K randomly chosen attributes at each node. 
Models were developed by changing this parameter between 1 and the maximum number of molecular 
descriptors used for model development (19, 18, and 22 descriptors for the inhibition, ATPase 
activation, and monolayer efflux experiments, respectively). Thus, no more than 10 descriptors (with a 
minimum number of 5) were involved in the best-performing decision trees (Table 5). This number of 
descriptors appears to be suitable for the size of the dataset exploited when using classifications 
approaches. No maximum depth for the tree was fixed. The minimum total weight of the instances in a 
leaf was set to 1 and 20 different random seeds were used. 
In C4.5, pruning was used by setting the confidence factor to 0.25 (default value). The minimum 
number of instances (compounds) per leaf varied from 1 to 5. The amount of data (NumFolds) for 
reduced-error pruning was also varied. 
In all cases, we tried to obtain statistically validated decision tree models that were as small as 
possible and that had large leaf nodes. This would then lead to models that were probably easier to 
interpret and that had a better predictive power (e.g., a leaf with 100 compounds in it will have more 
predictive power than one with just one or two compounds).  
3.3. Statistical Validation 
Parameters needed for model validation were computed and analyzed for the validation step for 
both the training (internal validation) and the selected test set (external validation). 
Leave-one-out cross validation on the training sets was employed for the internal validation and to 
assess the robustness of the model. Models were estimated on the basis of true positives (TP), or 
sensitivity (fraction of “class Y” molecules correctly classified), true negatives (TN) or specificity, 
(fraction of “class N” molecules correctly classified), and accuracy (fraction of molecules correctly 
classified) on the Training set. Other statistics were considered, such as the Matthews Correlation 
Coefficient (MCC) [31], the K statistic [32], and the area under the Receiver Operating Characteristic 
(ROC) curve (AUC) [33]. 
The MCC is a measure of the quality of classification. It is expressed by values ranging between −1 
and +1, where +1 represents a perfect prediction, 0 an average random prediction, and −1 means an 
inverse prediction. The MCC is considered one of the best parameters to estimate what is reported in 
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the so-called confusion matrix with regard to true and false positives and negatives. The equation used 
for computing MCC values is the following: 
( ) ( )
( )( )( ) )( FNTNFPTNFNTPFPTP
FNFPTNTPMCC
++++
×−×
=  
where TP is the number of true positives, TN the number of true negatives, FP the number of false 
positives (“class N” compounds predicted as “class Y”), and FN the number of false negatives (“class 
Y” compounds predicted as “class N”). The advantage of the MCC is that it can be used to evaluate the 
quality of classification models even when developed on an unbalanced dataset. 
K is the chance-corrected proportional agreement: it is an index that compares the agreement found 
versus the agreement that might be expected by chance. K = 1 corresponds to a perfect agreement, K = 0 
means an agreement equal to what expected by chance, and K = −1 means complete disagreement. 
The ROC curve can be represented by plotting the fraction of TP (or sensitivity) versus the fraction 
of FP (or 1-specificity). The ROC analysis helps to select optimal classification models and to discard 
the suboptimal ones. The ROC curve provides a criterion based on the so-called AUC (Area Under the 
ROC curve), which is an index of goodness of the classification model: a perfect CM shows AUC = 1. 
When evaluating the results of a classification model, the reference status is generally considered as 
the one where all of the objects are assigned to the class that is most represented. This reference 
condition corresponds to the absence of a model, and is therefore called a No-model condition. 
Statistical parameters similar to those obtained for the No-model status provide evidence of poor 
results from the classification model, as the No-model value is unique and does not depend on the 
classification method used. 
3.4. Applicability Domain 
Several methods to define the Applicability Domain of a QSAR model have been reported in the 
literature; in this work, we exploited a distance-based method [34]. In this approach, the applicability 
domain (AD) where the model is expected to give reliable predictions is defined through a  
similarity-based criterion. This enables us to leave out from the prediction task those compounds 
whose structural features were poorly sampled in the training set and whose predictions are not reliable.  
In order to estimate structural similarity, each compound was represented by a point in the  
N-dimensional descriptor space (where N is the total number of descriptors); its coordinates (X1, X2, …, XN, 
where Xi) take the values of each individual descriptor. The molecular similarity between all the pairs of 
molecules was measured in terms of the Euclidean distance between their representative points. 
Compounds with the smallest distance between them have the highest similarity.  
In addition, we needed to define a centroid of the training set: this was calculated as a point in the 
N-dimensional descriptors space with coordinates 1X , 2X , …, NX , where iX  is the average value of 
the i descriptor within the training set. The Euclidean distances between the centroid and each of the 
molecules of the training set were then computed, so that the minimum and maximum distances from 
the centroid were used to define the AD (allowed range). Test set and external set compounds that 
have to be subjected to the prediction task must fall within the AD of the model: the distances between 
each molecule and the centroid must be included within the allowed range. 
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The consensus model obtained from each experiment was constructed by averaging all available 
predicted values by taking into account the applicability domain of each individual model.  
Since each model had its unique way of defining the AD, each compound of the test set and the 
external set could be found within the AD of one or more models constituting the consensus model, so 
only models “covering” the compound were used for averaging. The advantage of this method is that 
the overall coverage of the prediction is still high since it is rare to have an unknown compound 
outside of the defined ADs of all available models [23]. 
4. Conclusions  
P-gp inhibition may be considered as a valid approach to improve drug bioavailability as well as to 
overcome the drug resistance to many kind of tumours characterized by an over-expression of this 
protein. The development of predictive models for identifying “true” P-gp inhibitors could be valuable 
in selecting new chemical entities that inhibit P-gp without affecting ATPase activity and that are not 
actively effluxed by P-gp. 
Three experiments to develop classification models aimed at identifying “true” P-gp inhibitors were 
thus performed. The study was carried out using decision tree algorithms on a unique dataset of  
59 compounds for which data referring to inhibition, ATPase activation and monolayer efflux assays 
were available. The predictive power of the models was assessed using a LOO-CV for internal 
validation and a selected test set for the external validation. This two-step validation led to a pool of  
best-performing models for each experiment, which were used as a consensus model that showed a 
better performance than any single model. Furthermore, the consensus models correctly identified the 
“true” inhibitors from the additional external set of compounds that we had synthesized. The molecular 
descriptors characterizing the best-performing classification models appeared to be involved (within 
each experiment) in different trees, thus confirming the stability and reliability of the models. The 
analysis of the decision trees suggested a pool of molecular features that could help in the development 
of new chemical entities potentially endowed with the typical profile of a “true”-inhibitor. 
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